Generate a tailored SOP for Dr. Yael Mosse. Improve your application with a focused, well-structured draft.
Yael P. Mosse, M.D. is a professor in the Department of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania, affiliated with the Children's Hospital of Philadelphia. With a focus on neuroblastoma, she has significantly contributed to the understanding of the hereditary basis of this childhood cancer. Her seminal research on activating mutations in the Anaplastic Lymphoma Kinase (ALK) oncogene has paved the way for novel therapeutic strategies and molecular diagnostics for neuroblastoma. Mosse's work led to the completion of a multi-institutional pediatric phase 1 trial utilizing the ALK inhibitor crizotinib, showcasing the successful translation of basic science discoveries into clinical application. As a physician-scientist, she co-leads a major developmental therapeutics program aimed at treating children with refractory neuroblastoma, emphasizing the importance of targeted therapies and innovative treatment approaches. Her research continues to impact the field of pediatric oncology, particularly in identifying new therapeutic avenues for neuroblastoma and enhancing treatment outcomes for patients with this challenging disease.
Perelman School of Medicine, University of Pennsylvania • Philadelphia, PA
Leading research on pediatric neuroblastoma and targeted therapies.
Wharton Doctoral programs cover fields like Finance, Marketing, Management, and Operations, Information and Decisions.